Suchergebnisse - "Rubovszky, Gábor"

PubPharm (51)

1

TROPION-Breast01 : Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer

enthalten in: Future oncology (London, England) | 2024

von Bardia, A. | Jhaveri, K. | Kalinsky, K. | +21

2

Fertility preservation in female cancer patients.

enthalten in: Orvosi hetilap | 2023

von Vesztergom, D. | Székely, B. | Hegyi, B. | +6

3

Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer

enthalten in: The New England journal of medicine | 2023

von Turner, N. | Oliveira, M. | Howell, S. | +121

4

Corrigendum : Systemic treatment of breast cancer. 1st Central-Eastern European professional Consensus Statement on breast cancer

enthalten in: Pathology oncology research : POR | 2023

von Rubovszky, G. | Kocsis, J. | Boér, K. | +11

ErratumFor: Pathol Oncol Res. 2022 Jul 11;28:1610383. - PMID 35898593

5

Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors : The JAVELIN PARP Medley Nonrandomized Controlled Trial

enthalten in: JAMA oncology | 2023

von Yap, T. | Bardia, A. | Dvorkin, M. | +17

CommentOn: JAMA Oncol. 2023 Jan 1;9(1):25-27. - PMID 36394835

6

Influence of mutagenic versus non-mutagenic pre-operative chemotherapy on the immune infiltration of breast cancer

enthalten in: bioRxiv.org | 2022

von Tőkés, A. | Rusz, O. | Cserni, G. | +11

7

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

enthalten in: The New England journal of medicine | 2022

von Cortes, J. | Rugo, H. | Cescon, D. | +117

CommentIn: N Engl J Med. 2022 Jul 21;387(3):273-274. - PMID 35857664

8

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

enthalten in: The New England journal of medicine | 2022

von Modi, S. | Jacot, W. | Yamashita, T. | +136

CommentIn: Nat Rev Clin Oncol. 2022 Aug;19(8):493. - PMID 35778612

9

Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial

enthalten in: Radiology and oncology | 2022

von Borstnar, S. | Palacova, M. | Łacko, A. | +6

10

Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy : subgroup safety analysis from the phase 3b CompLEEment-1 trial

enthalten in: Radiology and oncology | 2022

von Borstnar, S. | Palacova, M. | Łacko, A. | +6

1
2
3
4
5
6
Nächster »
[6]